Search
Quinupristin
go.drugbank.com/drugs/DB01369ApprovedQuinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.
Interferon alfa-n1
go.drugbank.com/drugs/DB00011ApprovedWithdrawnInterferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produc...
Autologous peripheral blood-derived CD34+ cells
go.drugbank.com/drugs/DB16367ApprovedInvestigationalAutologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells. … [L27741] It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).
MK-0482
go.drugbank.com/drugs/DB17453InvestigationalMK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.
Methotrexate
go.drugbank.com/drugs/DB00563ApprovedInvestigational[A180322] Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma
Florquinitau (18F)
go.drugbank.com/drugs/DB19215Approved[L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease
Sodium phosphate, monobasic, unspecified form
go.drugbank.com/drugs/DB14503ApprovedMixtures: Up and Up Ready To Use EnemaFremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigational[L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018.
Crinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Standard therapy involves cortisol replacement, but typically requires supraphysiological glucocorticoid doses to lower both ACTH and adrenal androgens, resulting in chronic glucocorticoid overexposure … Patients with congenital adrenal hyperplasia (CAH) face two major problems: adrenal insufficiency, caused by insufficient endogenous cortisol production, and androgen excess, caused by a counter-regulatory
Mupirocin
go.drugbank.com/drugs/DB00410ApprovedInvestigationalVet approved[L10580] It primarily works by inhibiting bacterial protein synthesis. … _ and traumatic skin lesions due to secondary skin infections caused by _S. aureus_ and _S. pyogenes_.